DNA protein cross-links produced by NSC 652287, a novel thiophene derivative active against human renal cancer cells

Molecular Pharmacology

Volumn 56, Issue 3, 1999, Pages 478-484

  Nieves Neira, Wilberto ^a   Rivera, Maria I ^b   Kohlhagen, Glenda ^a   Hursey, Miriam L ^b   Pourquier, Philippe ^a   Sausville, Edward A ^b   Pommier, Yves ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Developmental Therapeutics Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,5 BIS(5 HYDROXYMETHYL 2 THIENYL)FURAN; ANTINEOPLASTIC AGENT; CELL DNA; DNA TOPOISOMERASE; PROTEIN P21; PROTEIN P53; THIOPHENE DERIVATIVE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CELL DESTRUCTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DNA CROSS LINKING; DNA DETERMINATION; DNA STRAND BREAKAGE; DOSE TIME EFFECT RELATION; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG STRUCTURE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MITOSIS INHIBITION; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN DNA BINDING;

EID: 0032838772     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.3.478     Document Type: Article

References (29)

1. Acton EM, Narayanan VL, Risbood PA, Shoemaker R, Vistica DT and Boyd MR (1994) Anticancer specificity of some ellipticinimu salts against human brain tumors in vitro. J Med Chem 37:2185-2189.
2. Alley MC, Scudiero DA, Monks A, Hursey ML, Czerwinski MJ, Fine DL, Abbott BJ, Mayo JG, Shoemaker RH and Boyd MR (1988) Feasibility of drug screening with panels of human tumor cell lines using a microculture tetrazolium assay. Cancer Res 48:589-601.
3. Bertrand R and Pommier Y (1995) Assessment of DNA damage in mammalian cells by DNA filtration methods, in Cell Growth and Apoptosis: A Practical Approach (Studzinski G ed) pp 96-117, IRL Press, Oxford University Press, Oxford.
4. Bubb MR, Senderowicz AMJ, Sausville EA, Duncan KLK and Korn ED (1994) Jasplakinolide, a cytotxic natural product, induces actin polymerization and competitively inhibits the binding of phalloidin to F-actin. J Biol Chem 269:14869-14871.
5. Carter CA, Waud WR, Plowman J and Alley MA (1996) In vivo spectrum of antitumor activity of a thiophene derivative. (Abstract). Proceedings of American Association for Cancer Research Meeting, Washington, DC, April 20-24, 1996, 37:393. American Association for Cancer Research, Philadelphia, PA.
6. Darzynkiewicz Z, Li X and Gong J (1994) Assays of cell viability: Discrimination of cells dying by apoptosis. Methods Cell Biol 41:15-38.
7. Duncan KL, Duncan MD, Alley MC, and Sausville EA (1996) Cucurbitacin E-induced disruption of the actin and vimentin cytoskeleton in prostate carcinoma cells. Biochem Pharmacol 52:1553-1560.
8. Gervais JL, Seth P and Zhang H (1998) Cleavage of CDK inhibitor p21(Cip1/Waf1) by caspases is an early event during DNA damage-induced apoptosis. J Biol Chem 273:19207-19212.
9. Jayaram HN, Gharehbaghi K, Rieser J, Krohn K and Paull KD (1992) Cytotoxicity of a new IMP dehydrogenase inhibitor, benzamide riboside, to human myelogenous leukemia K562 cells. Biochem Biophys Res Commun 186:1600-1606.
10. Kohlhagen G, Paull K, Cushman M, Nagafufuji P and Pommier Y (1998) Protein-linked DNA strand breaks induced by NSC 314622, a non-camptothecin topoisomerase I poison. Mo. Pharmacol 54:50-58.
11. Kohn KW (1996) DNA filter elution: A window on DNA damage in mammalian cells. Bioessays 18:505-513.
12. Kohn KW, Ewig RAG, Erickson LC and Zwelling LA (1981) Measurement of strand breaks and crosslinks by alkaline elution, in DNA Repair: A Laboratory Manual of Research Procedures (Friedberg EC and Hanawalt PC eds.) pp 379-401, Marcel Dekker New York.
13. Laemmli UK (1970) Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685.
14. Leteurtre F, Kohlhagen G, Paull KD and Pommier Y (1994) Topoisomerase II inhibition by anthrapyrazoles, DuP 937 & DuP 941 (Losoxanthrone) and cytotoxicity in the NCI cell screen. J Natl Cancer Inst 86:1239-1244.
15. Monks A, Scudiero DA, Johnson GS, Paull KD and Sausville EA (1997) The NCI anti-cancer drug screen: A smart screen to identify effectors of novel targets. Anticancer Drug Design 12:533-541.
16. Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, Hose C, Langley J, Cronise P, Vaigro-Wolff A, Gray-Goodrich M, Campbell H, Mayo J and Boyd M (1991) Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst 83:757-766.
17. O'Connor PM, Jackman J, Bae I, Myers TG, Fan S, Mutoh M, Scudiero DA, Monks A, Sausville EA, Weinstein JN, Friend S, Fornace AJ, Jr and Kohn KW (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285-4300.
18. Paull KD, Hamel E and Malpeis L (1995) Prediction of biochemical mechanism of action from the in vitro antitumor screen of the National Cancer Institute, in Cancer Chemotherapeutic Agents (Foye WO ed.) pp 8-45, American Cancer Society, Washington, DC.
19. Paull KD, Lin CM, Malspeis L and Hamel E (1992) Identification of novel antimitotic agents acting at the tubulin level by computer-assisted evaluation of differential cytotoxicity data. Cancer Res 52:3892-3900.
20. Paull KD, Shoemaker RH, Hodes L, Monks A, Scudiero DA, Rubinstein L, Plowman J and Boyd MR (1989) Display and analysis of patterns of differential activity of drugs against human tumor cell lines: Development of mean graph and COMPARE algorithm. J Natl Cancer Inst 81:1088-1092.
21. Pommier Y, Covey JM, Kerrigan D, Markovits J and Pham R (1987) DNA unwinding and inhibition of mouse leukemia L1210 DNA topoisomerase I by intercalators. Nucleic Acids Res 15:6713-6731.
22. Pommier Y, Kohlhagen G, Kohn F, Leteurtre F, Wani MC and Wall ME (1995) Interaction of an alkylating camptothecin derivative with a DNA base at topoisomerase I-DNA cleavage sites. Proc Natl Acad Sci USA 92:8861-8865.
23. Rivera MI, Stinson SF, Vistica DT, Jorden JL, Kenney S and Sausville EA (1999) Selective toxicity of the tricyclic thiophene NSC 652287 in renal carcinoma cell lines: Differential accumulation and metabolism. Biochem Pharmacol 57:1283-1295.
24. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, Currens MJ, Seniff D and Boyd MR (1988) Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res 48:4827-4833.
25. Sedlacek H, Czech J, Naik R, Kaur G, Worland P, Losiewicz M, Parker B, Carlson B, Smith A, Senderowicz A and Sausville EA (1996) Flavopiridol(L86-8275; NSC 649890), a new kinase inhibitor for tumor therapy. Int J Oncol 9:1143-1168.
26. Seynaeve CM, Kazanietz MG, Blumberg PM, Sausville EA and Worland PJ (1994) Differential inhibition of protein kinase C isozymes by UCN-01, a staurosporine analogue. Mol Pharmacol 45:1207-1214.
27. Solary E, Leteurtre F, Paull KD, Scudiero D, Hamel E and Pommier Y (1993) Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent. Biochem Pharmacol 45:2449-2456.
28. Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, Kenney S, Keller J and Boyd MR (1992) Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 12:1035-1053.
29. Vistica DT, Kenney S, Hursey M and Boyd MR (1996) Role of membrane potential in the accumulation of quarternized ellipticines by human tumor cell lines. J Pharmacol Exp Ther 279:1018-1025.